Inflammatory biomarkers in acute coronary syndromes. Part IV: Matrix metalloproteinases and biomarkers of platelet activation

Circulation

Volumn 113, Issue 9, 2006, Pages

  Armstrong, Ehrin J ^a   Morrow, David A ^b   Sabatine, Marc S ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CD40 LIGAND; COLLAGEN TYPE 4; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; PADGEM PROTEIN; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN I; MATRIX METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS; ACUTE DISEASE; ANIMAL; CORONARY ARTERY DISEASE; INFLAMMATION; PHYSIOLOGY; THROMBOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; BIOLOGICAL MARKERS; CORONARY DISEASE; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; PLATELET ACTIVATION;

EID: 33645517268     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.595553     Document Type: Review

References (21)

1. Galis Z, Khatri J. Matrix metalloproteinases in vascular modeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2003;90:251-262.
2. Creemers E, Cleutjens J, Smits J, Daemen M. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210.
3. Galis Z, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
4. Eckart R, Uyehara C, Shry E, Furgerson J, Krasuski R. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol. 2004;17:27-31.
5. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368-372.
6. Soejima H, Ogawa H, Sakamoto T, Miyamoto S, Kajiwara I, Kojima S, Hokamaki J, Sugiyama S, Yoshimura M, Suefuji H, Miyao Y, Fujimoto K, Miyagi H, Kishikawa H. Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ J. 2003;67:301-304.
7. Lawrence J, Oxvig C, Overgaard M, Sottrup-Jensen L, Gleich G, Hays L, Yates J, Conover C. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96:3149-3153.
8. Nichols T, du Laney T, Zheng B, Bellinger D, Nichols G, Engleman W, Clemmons D. Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-1-mediated signaling. Circ Res. 1999;85:1040-1045.
9. Bayes-Genis A, Schwartz R, Lewis D, Overgaard M, Christiansen M, Oxvig C, Ashai K, Holmes D, Conover C. Insulin-like growth factor binding protein-4 protease produced by smooth muscle cells increases in the coronary artery after angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:335-341.
10. Bayes-Genis A, Conover C, Overgaard M, Bailey K, Christiansen M, Holmes D, Virmani R, Oxvig C, Schwartz R. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
11. Lund J, Qin Q, Ilva T, Pettersson K, Voipio-Pulkki L, Porela P, Pulkki K. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924-1926.
12. Heeschen C, Dimmeler S, Hamm C, Fichtlscherer S, Simoons M, Zeiher A. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes. J Am Coll Cardiol. 2005;45:229-237.
13. Mach F, Schonbeck U, Sukhova G, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
14. Henn V, Steinbach S, Buchner K, Presek P, Kroczek R. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047-1054.
15. Freedman J, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation. 2002;105:2130-2132.
16. Andre P, Prasad K, Denis C, He M, Papalia J, Hynes R, Phillips D, Wagner D. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
17. Inwald D, McDowall A, Peters M, Callard R, Klein N. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92:1041-1048.
18. Heeschen C, Dimmeler S, Hamm C, van den Brand M, Boersma E, Zeiher A, Simoons M. Soluble CD40L in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
19. Varo N, de Lemos J, Libby P, Morrow D, Murphy S, Nuzo R, Gibson M, Cannon C, Braunwald E, Schonbeck U. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108:1049-1052.
20. Merten M, Chow T, Hellums D, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation. 2000;102:2045-2050.
21. Hollander J, Muttreja M, Dalesandro M, Shofer F. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol. 1999;34:95-105.